Long-Term Data Support Dolutegravir-, Fostemsavir-Based Regimens in MDR HIV-1
|
In VIKING-3, the proportion of dolutegravir-treated
patients who had an HIV-1 RNA level below 50 copies/mL was 69% at 24
weeks and 63% at 48 weeks. At ... |
NICE rejects long-acting HIV prevention treatment for NHS use
Lenacapavir, a twice-yearly injection to reduce the risk of HIV infection, should not be routinely available as preventative treatment. View article...